Table 3.
Effect of mass drug administration (MDA) on ADL episodes and stage of lymphedema pre- and post-intervention for 117 lymphedema patients, Léogane, Haiti, 1995–2008
| Outcome | Ratio for year increase among those who received MDA | Ratio for year increase among those who did not receive MDA | Comparison of ratios (received MDA/did not receive MDA) | 95% confidence interval for comparison of ratios | P |
|---|---|---|---|---|---|
| ADL episodes* | |||||
| Pre-intervention | 0.64 | 0.56 | 1.14 | 0.81–1.64 | 0.44 |
| Post-intervention | 1.23 | 1.29 | 0.95 | 0.80–1.13 | 0.57 |
| Stage of lymphedema† | |||||
| Pre-intervention | 0.95 | 0.99 | 0.96 | 0.68–1.35 | 0.82 |
| Post-intervention | 0.94 | 0.94 | 1.00 | 0.84–1.21 | 0.93 |
*
Ratio reported is rate ratio. Adjusted for model-specific variables by using generalized estimating equations (GEEs) repeated measures Poisson regression. Defined as the number of adenolymphangitis (ADL) episodes per year.
†
Ratio reported is odds ratio for both stage category 3 vs. categories 2 and 1 and for stage categories 3 and 2 vs. category 1. Adjusted for model-specific variables by using a GEE repeated measures cumulative logistic regression.